Clinical impact of DPYD genotyping and dose adjustment in candidates for fluoropyrimidine treatment.

Image 1.

DPYD variant testing in candidates for fluoropyrimidine treatment: A study protocol.

Objective: The main purpose of this study is to evaluate the potential clinical impact of pharmacogenetic testing on the reduction of the toxicity in patients treated with fluoropyrimidines. This will be achieved by  comparing the frequency of adverse events and the incidence of toxicity of two groups of patients that will differ from each other only in that one  will receive pharmacogenetic counseling. The hypothesis is that availability of a pharmacogenetic report prior to treatment initiation has a positive  effect.

Clinical efficacy and safety of anti PD-1/PD-L1 antibodies as monotherapy in patients with non-small-cell lung cancer.

Objective: To evaluate the efficacy and safety of anti-PD-1 and anti-PD-L1 immunotherapy agents as monotherapy in patients with non-small cell  lung cancer.

Method: This was a four-year retrospective observational study that included all patients with non-small cell lung cancer treated with  nivolumab, pembrolizumab, and atezolizumab in a third level hospital. Demographic, clinical (ECOG status, stage, PD-L1 expression  level), therapeutic (drug, start date, line of treatment and number of  cycles), efficacy (date and status at the end of follow-up) and toxicity  variables were collected.